{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:17:30Z","timestamp":1789168650352,"version":"build-2803163510"},"reference-count":41,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"unspecified","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Faculty of Medicine, Ramathibodi Hospital, Mahidol University","award":["No.64004"],"award-info":[{"award-number":["No.64004"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,6,8]]},"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Dry eye disease (DED) is a common eye problem. Although the disease is not fatal, it substantially reduces quality of life and creates a high economic burden, especially in patients with moderate-to-severe DED. Several biological tear substitutes (eg, autologous serum (AS), autologous platelet-rich plasma (APRP) and autologous platelet lysate) could effectively improve dry eyes. However, evidence on their comparative efficacy is controversial. This study aims to compare the efficacy of 100% APRP with 100% AS eye drops in patients with moderate-to-severe DED.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The study is a single-centre, double-blinded randomised, parallel, non-inferiority trial. One hundred and thirty patients with moderate-to-severe DED, aged 18\u201370 years will be recruited from outpatient clinic, Department of Ophthalmology, Ramathibodi Hospital, Bangkok from February 2021 to January 2023. Patients will be randomised to receive either 100% APRP or 100% AS eye drops (1:1 ratio) for 4 weeks. The primary outcomes are ocular surface disease index (OSDI) and ocular surface staining (OSS) evaluated using the Oxford scale. Secondary outcomes are fluorescein break-up time, Schirmer\u2019s I test, meibomian gland parameters and adverse events. Other measured outcomes include best-corrected visual acuity, intraocular pressure and compliance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study protocol and any supplements used in conducting this trial have been approved by the Ethics Committee of Faculty of Medicine, Ramathibodi Hospital, Mahidol University (MURA2020\/1930). Informed consent will be obtained from all patients before study entry. Results will be presented in peer-reviewed journals and international conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial pre-results\" xlink:href=\"NCT04683796\">NCT04683796<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-048479","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T12:35:45Z","timestamp":1625056545000},"page":"e048479","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Comparison of treatment efficacy between 100% platelet-rich plasma and 100% serum eye drops in moderate-to-severe dry eye disease: a randomised controlled trial protocol"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct04683796","registry":"10.18810\/clinical-trials-gov","type":"preResults"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8203-2353","authenticated-orcid":false,"given":"Passara","family":"Jongkhajornpong","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"},{"name":"Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawin","family":"Numthavaj","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1002-8536","authenticated-orcid":false,"given":"Thunyarat","family":"Anothaisintawee","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"},{"name":"Department of Family Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaevalin","family":"Lekhanont","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8197-6280","authenticated-orcid":false,"given":"Gareth","family":"McKay","sequence":"additional","affiliation":[{"name":"Centre for Public Health, Faculty of Medicine Health and Life Sciences, Queen\"s University Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9800-1308","authenticated-orcid":false,"given":"John","family":"Attia","sequence":"additional","affiliation":[{"name":"Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, Faculty of Health and Medicine, University of Newcastle, and Hunter Medical Research Institute, Newcastle, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammarin","family":"Thakkinstian","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"key":"2025121407333249000_11.6.e048479.1","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jtos.2017.08.003","article-title":"TFOS DEWS II report executive summary","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"key":"2025121407333249000_11.6.e048479.2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II epidemiology report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul Surf"},{"key":"2025121407333249000_11.6.e048479.3","doi-asserted-by":"publisher","DOI":"10.1097\/01.ico.0000244875.92879.1a"},{"key":"2025121407333249000_11.6.e048479.4","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e3181f7f363"},{"key":"2025121407333249000_11.6.e048479.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2020.02.007"},{"key":"2025121407333249000_11.6.e048479.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.006"},{"key":"2025121407333249000_11.6.e048479.7","doi-asserted-by":"crossref","first-page":"DES121","DOI":"10.1167\/iovs.17-23760","article-title":"Autologous serum and serum components","volume":"59","author":"Higuchi","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2025121407333249000_11.6.e048479.8","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e31817f3a0e"},{"key":"2025121407333249000_11.6.e048479.9","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-27492008000700010"},{"key":"2025121407333249000_11.6.e048479.10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fmed.2018.00033","article-title":"Reflections on dry eye syndrome treatment: therapeutic role of blood products","volume":"5","author":"Drew","year":"2018","journal-title":"Front. Med."},{"key":"2025121407333249000_11.6.e048479.11","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3390\/jcm8091478","article-title":"Blood-Based treatments for severe dry eye disease: the need of a consensus","volume":"8","author":"Bernabei","year":"2019","journal-title":"JCM"},{"key":"2025121407333249000_11.6.e048479.12","doi-asserted-by":"publisher","DOI":"10.1097\/00008505-200110000-00002"},{"key":"2025121407333249000_11.6.e048479.13","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-014-2599-1"},{"key":"2025121407333249000_11.6.e048479.14","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/02713683.2016.1255758","article-title":"Comparison of autologous serum versus preservative free artificial tear in patients with dry eyes due to systemic isotretinoin therapy","volume":"42","author":"Y\u0131lmaz","year":"2017","journal-title":"Curr Eye Res"},{"key":"2025121407333249000_11.6.e048479.15","doi-asserted-by":"publisher","DOI":"10.3109\/02713683.2012.674609"},{"key":"2025121407333249000_11.6.e048479.16","doi-asserted-by":"crossref","unstructured":"Garc\u00eda\u2010Conca V , Abad\u2010Collado M , Hueso\u2010Abancens JR , et al . Efficacy and safety of treatment of hyposecretory dry eye with platelet\u2010rich plasma. Acta Ophthalmol 2019;97.doi:10.1111\/aos.13907","DOI":"10.1111\/aos.13907"},{"key":"2025121407333249000_11.6.e048479.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.001"},{"key":"2025121407333249000_11.6.e048479.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.10.044"},{"key":"2025121407333249000_11.6.e048479.19","doi-asserted-by":"publisher","DOI":"10.2174\/138920112800624355"},{"key":"2025121407333249000_11.6.e048479.20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40123-016-0051-9","article-title":"Solid platelet rich plasma in corneal surgery","volume":"5","author":"Arnalich","year":"2016","journal-title":"Ophthalmol Ther"},{"key":"2025121407333249000_11.6.e048479.21","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.118.5.615"},{"key":"2025121407333249000_11.6.e048479.22","first-page":"221","article-title":"Report of the National eye Institute\/Industry workshop on clinical trials in dry eyes","volume":"21","author":"Lemp","year":"1995","journal-title":"Clao J"},{"key":"2025121407333249000_11.6.e048479.23","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.ajo.2014.02.012","article-title":"Reliability of 4 clinical grading systems for corneal staining","volume":"157","author":"Chun","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"2025121407333249000_11.6.e048479.24","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6997a"},{"key":"2025121407333249000_11.6.e048479.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.08.018"},{"key":"2025121407333249000_11.6.e048479.26","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1089\/jop.2016.0166","article-title":"The effect of immunologically safe plasma rich in growth factor eye drops in patients with Sj\u00f6gren syndrome","volume":"33","author":"Sanchez-Avila","year":"2017","journal-title":"J of Ocular Ther"},{"key":"2025121407333249000_11.6.e048479.27","doi-asserted-by":"publisher","DOI":"10.3109\/02713683.2012.720340"},{"key":"2025121407333249000_11.6.e048479.28","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2009.356"},{"key":"2025121407333249000_11.6.e048479.29","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwp425"},{"key":"2025121407333249000_11.6.e048479.30","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.psych.58.110405.085530"},{"key":"2025121407333249000_11.6.e048479.31","doi-asserted-by":"publisher","DOI":"10.1111\/opo.12009"},{"key":"2025121407333249000_11.6.e048479.32","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/opo.12399","article-title":"Recommendations for analysis of repeated-measures designs: testing and correcting for sphericity and use of manova and mixed model analysis","volume":"37","author":"Armstrong","year":"2017","journal-title":"Ophthalmic Physiol Opt"},{"key":"2025121407333249000_11.6.e048479.33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000251","article-title":"Consort 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"7","author":"Schulz","year":"2010","journal-title":"PLoS Med"},{"key":"2025121407333249000_11.6.e048479.34","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyx275","article-title":"An introduction to instrumental variables for epidemiologists","volume":"47","author":"Greenland","year":"2018","journal-title":"Int J Epidemiol"},{"key":"2025121407333249000_11.6.e048479.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2015.07.056"},{"key":"2025121407333249000_11.6.e048479.36","first-page":"200","article-title":"Serum eye drops for the treatment of ocular surface diseases: a systematic review and meta-analysis","volume":"17","author":"Franchini","year":"2019","journal-title":"Blood Transfus"},{"key":"2025121407333249000_11.6.e048479.37","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40123-017-0100-z","article-title":"Treatment of dry eye disease with autologous platelet-rich plasma: a prospective, interventional, Non-Randomized study","volume":"6","author":"Alio","year":"2017","journal-title":"Ophthalmol Ther"},{"key":"2025121407333249000_11.6.e048479.38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/8406832","article-title":"The effect of autologous platelet lysate eye drops: an in vivo confocal microscopy study","volume":"2016","author":"Fea","year":"2016","journal-title":"Biomed Res Int"},{"key":"2025121407333249000_11.6.e048479.39","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2019-314859"},{"key":"2025121407333249000_11.6.e048479.40","doi-asserted-by":"crossref","DOI":"10.1038\/srep38143","article-title":"Undiluted serum eye drops for the treatment of persistent corneal Epitheilal defects","volume":"6","author":"Lekhanont","year":"2016","journal-title":"Sci Rep"},{"key":"2025121407333249000_11.6.e048479.41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/521315","article-title":"Topical 100% serum eye drops for treating corneal epithelial defect after ocular surgery","volume":"2013","author":"Lekhanont","year":"2013","journal-title":"Biomed Res Int"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-048479","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T15:33:39Z","timestamp":1765726419000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-048479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6,30]]},"published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1136\/bmjopen-2020-048479"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-048479","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}